4756 Federal Register / Vol. 74, No. 16 / Tuesday, January 27, 2009 / Notices 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Communication 

Disorders Review Committee. 

Date: February 11–13, 2009. 

Time: February 11, 2009, 8 p.m. to 10 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Baltimore Marriott Waterfront, 700 

Aliceanna Street, Baltimore, MD 21202. 

Time: February 12, 2009, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Baltimore Marriott Waterfront, 700 

Aliceanna Street, Baltimore, MD 21202. 

Time: February 13, 2009, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Baltimore Marriott Waterfront, 700 

Aliceanna Street, Baltimore, MD 21202. 

Contact Person: Shiguang Yang, DVM, 

PhD, Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, NIDCD, NIH, 6120 Executive 

Blvd., Suite 400C, Bethesda, MD 20892, 301– 

435–1425, yangshi@nidcd.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: January 16, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–1665 Filed 1–26–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Multi-Domain Amphipathic 

Helical Peptides for the Treatment of 

Cardiovascular Diseases 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

contemplating the grant of an exclusive 

license worldwide to practice the 

invention embodied in: United States 

Provisional Patent Application No. 60/ 

619,392, filed October 15, 2004, entitled 

‘‘Multi-Domain Amphipathic Helical 

Peptides and Methods of Their Use’’ 

(HHS Ref. No. E–114–2004/0–US–01), 

United States Patent Application Serial 

No. 11/577,259, filed April 13, 2007, 

entitled ‘‘Multi-Domain Amphipathic 

Helical Peptides and Methods of Their 

Use’’ (HHS Ref. No. E–114–2004/0–US– 

07); Australian Patent Application 

Serial No. 2005295640, filed October 14, 

2005, entitled ‘‘Multi-Domain 

Amphipathic Helical Peptides and 

Methods of Their Use’’ (HHS Ref. No. E– 

114–2004/0–AU–03); Canadian Patent 

Application Serial No. 2584048, filed 

October 14, 2005, entitled ‘‘MultiDomain Amphipathic Helical Peptides 

and Methods of Their Use’’ (HHS Ref. 

No. E–114–2004/0–CA–04); European 

Patent Application Serial No. 

05815961.7, filed October 14, 2005, 

entitled ‘‘Multi-Domain Amphipathic 

Helical Peptides and Methods of Their 

Use’’ (HHS Ref. No. E–114–2004/0–EP– 

05); Japanese Patent Application Serial 

No. 2007–536912, filed October 14, 

2005, entitled ‘‘Multi-Domain 

Amphipathic Helical Peptides and 

Methods of Their Use’’ (HHS Ref. No. E– 

114–2004/0–JP–06) to KineMed, Inc., 

having a place of business in the State 

of California. The field of use may be 

limited to FDA or foreign regulatory 

body approved 5a peptide therapeutic 

for the prevention and treatment of 

cardiovascular diseases. The United 

States of America is the assignee of the 

patent rights in this invention. The 

territory may be worldwide. This 

announcement is the second notice to 

grant an exclusive license to this 

technology and supersedes any previous 

announcements including the Notice 

published in the Federal Register on 

Wednesday, May 11, 2005 (70 FR 

24832). 

DATES: Only written comments and/or 

application for a license, which are 

received by the NIH Office of 

Technology Transfer on or before March 

30, 2009 will be considered. 

ADDRESSES: Requests for a copy of the 

patent applications, inquiries, 

comments and other materials relating 

to the contemplated license should be 

directed to: Fatima Sayyid, M.H.P.M., 

Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–4521; Facsimile: (301) 402– 

0220; e-mail: 

Fatima.Sayyid@nih.hhs.gov. 

SUPPLEMENTARY INFORMATION: Clearance 

of excess cholesterol from cells by high 

density lipoproteins (HDL) is facilitated 

by the interaction of HDL 

apolipoprotein with cell surface binding 

sites or receptors such as ABCA1. 

ABCA1 is a member of the ATP binding 

cassette transporter family and is 

expressed by many cell types. Mutations 

in the ABCA1 transporter lead to 

diseases characterized by the 

accumulation of excess cellular 

cholesterol, low levels of HDL and an 

increased risk for cardiovascular 

disease. Research has demonstrated an 

inverse correlation between the 

occurrence of atherosclerotic events and 

levels of HDL and its most abundant 

protein constituent, apolipoprotein A–1 

(apoA–1). ApoA–1 has been shown to 

promote lipid efflux from ABCA1 

transfected cells. However, the nature of 

the interaction between apoA–1 and 

ABCA1 is not fully understood. Several 

other exchangeable type apolipoproteins 

have been shown to efflux lipid from 

ABCA1 transfected cells. Although the 

exchangeable type apolipoproteins do 

not share a similar primary amino acid 

sequence, they all contain amphipathic 

helices, a structural motif known to 

facilitate the interaction of proteins with 

lipids. Recently, it has been shown in 

both animal models and humans that 

intravenous administration of apoA–1 

can reduce the size of atherosclerotic 

plaques. It has also been observed that 

synthetic peptide mimics of apoA–1 can 

promote efflux of excess cholesterol 

from cells. Therefore, synthetic mimics 

of apoA–1 can potentially also be used 

as therapeutic compounds in the 

prevention and treatment of 

atherosclerosis. 

Currently, there are a wide variety of 

treatments for dyslipidemia, which 

include, but are not limited to, 

pharmacologic regimens (mostly 

statins), partial ileal bypass surgery, 

portacaval shunt, liver transplantation, 

and removal of atherogenic lipoproteins 

by one of several apheresis procedures. 

The subject technology is related to 

peptides and peptide analogs with 

multiple amphipathic alpha-helical 

domains that promote lipid efflux from 

cells and it relates to methods for 

identifying non-cytotoxic peptides that 

promote lipid efflux from cells that are 

useful in the treatment and prevention 

of dyslipidemic and vascular disorders. 

Dyslipidemic and vascular disorders 

amenable to treatment with the isolated 

multi-domain peptides include, but are 

not limited to, hyperlipidemia, 

hyperlipoproteinemia, 

mstockstill on PROD1PC66 with NOTICES6

Federal Register / Vol. 74, No. 16 / Tuesday, January 27, 2009 / Notices 4757 

hypercholesterolemia, 

hypertriglyceridemia, HDL deficiency, 

apoA-I deficiency, coronary artery 

disease, atherosclerosis, thrombotic 

stroke, peripheral vascular disease, 

restenosis, acute coronary syndrome, 

and reperfusion myocardial injury. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: January 21, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–1754 Filed 1–26–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Prevention; Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given of the meeting of 

the Center for Substance Abuse 

Prevention’s (CSAP) National Advisory 

Council on February 10, 2009. 

The meeting is open and will include 

discussion of the Center’s policy issues, 

and current administrative, legislative 

and program developments. 

Attendance by the public will be 

limited to space available. Public 

comments are welcome. Please 

communicate with the CSAP Council’s 

Designated Federal Official, Ms. Tia 

Haynes (see contact information below), 

to make arrangements to attend, 

comment or to request special 

accommodations for persons with 

disabilities. 

Substantive program information, a 

summary of the meeting, and a roster of 

Council members may be obtained as 

soon as possible after the meeting, either 

by accessing the SAMHSA Committee 

Web site, https://nac.samhsa.gov/ 

CSAPcouncil/index.aspx, or by 

contacting Ms. Haynes. The transcript 

for the open session will also be 

available on the SAMHSA Council Web 

site within three weeks after the 

meeting. 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration, Center for Substance 

Abuse Prevention National Advisory 

Council. 

Date/Time/Type: February 10, 2009. 

From 1 p.m.–5 p.m.: Open. 

Place: Gaylord Convention Center, 

201 Waterfront Street, National Harbor 

Room–4 & 5, National Harbor, MD 

20745. 

Contact: Tia Haynes, Designated 

Federal Official, SAMHSA/CSAP 

National Advisory Council, 1 Choke 

Cherry Road, Room 4–1066, Rockville, 

MD 20857, Telephone: (240) 276–2436, 

FAX: (240) 276–2430, E-mail: 

tia.haynes@samhsa.hhs.gov. 

Toian Vaughn, 

Committee Management Officer, Substance 

Abuse and Mental Health, Services 

Administration. 

[FR Doc. E9–1683 Filed 1–26–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Extension of Agency Information 

Collection Activity Under OMB Review: 

Federal Flight Deck Officer Program 

AGENCY: Transportation Security 

Administration, DHS. 

ACTION: 30-day notice. 

SUMMARY: This notice announces that 

the Transportation Security 

Administration (TSA) has forwarded the 

Information Collection Request (ICR), 

OMB control number 1652–0011, 

abstracted below to the Office of 

Management and Budget (OMB) for 

review and approval of an extension of 

the currently approved collection under 

the Paperwork Reduction Act. The ICR 

describes the nature of the information 

collection and its expected burden. TSA 

published a Federal Register notice, 

with a 60-day comment period soliciting 

comments, of the following collection of 

information on November 19, 2008, 73 

FR 69670. The collection requires 

interested volunteers to fill out an 

application to determine their 

suitability for participating in the 

Federal Flight Deck Officer (FFDO) 

Program, and deputized FFDOs to 

submit written reports of certain 

prescribed incidents. 

DATES: Send your comments by 

February 26, 2009. A comment to OMB 

is most effective if OMB receives it 

within 30 days of publication. 

ADDRESSES: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget. Comments should be addressed 

to Desk Officer, Department of 

Homeland Security/TSA, and sent via 

electronic mail to 

oira_submission@omb.eop.gov or faxed 

to (202) 395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Ginger LeMay, Office of Information 

Technology, TSA–11, Transportation 

Security Administration, 601 South 

12th Street, Arlington, VA 22202–4220; 

telephone (571) 227–3616; facsimile 

(571) 227–2907. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

In accordance with the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.), an agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a valid OMB control 

number. The ICR documentation is 

available at www.reginfo.gov. Therefore, 

in preparation for OMB review and 

approval of the following information 

collection, TSA is soliciting comments 

to— 

(1) Evaluate whether the proposed 

information requirement is necessary for 

the proper performance of the functions 

of the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including using 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Information Collection Requirement 

Title: Federal Flight Deck Officer 

Program. 

Type of Request: Extension of a 

currently approved collection. 

OMB Control Number: 1652–0011. 

Forms(s): N/A. 

Affected Public: Volunteer pilots, 

flight engineers, and navigators. 

Abstract: The Federal Flight Deck 

Officer (FFDO) Program enables TSA to 

mstockstill on PROD1PC66 with NOTICES6